Press Releases

Date Title and Summary View
Jan 04, 2023
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD , Jan. 04, 2023 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41 st Annual J.P.
Jan 04, 2023
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
ROCKVILLE, MD , Jan. 04, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A.
Nov 17, 2022
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD , Nov. 17, 2022 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S.
Nov 03, 2022
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end Anticipated update on lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecule) monotherapy clinical data in first
Nov 02, 2022
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Nov. 02, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
Oct 26, 2022
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD , Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Oct 17, 2022
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
– Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART ® Molecule with Potential to Treat Various Hematologic Malignancies – –   Potential for Companies to Collaborate on Two Additional Future Research Programs – FOSTER CITY, Calif. & ROCKVILLE, Md. --(BUSINESS WIRE)--Oct.
Sep 02, 2022
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
Aug 08, 2022
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies Plan to initiate MGC018 Phase 2/3 study in prostate cancer by year-end Initiates cost-saving measures through corporate restructuring with focus on key clinical programs, extending cash runway into 2024 with
Jul 25, 2022
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD , July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Jul 08, 2022
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
ROCKVILLE, MD , July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of July 7, 2022 , the Company closed the
Jun 08, 2022
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD , June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
May 23, 2022
MacroGenics Announces Appointment of William Heiden to Board of Directors
ROCKVILLE, MD , May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors,
May 17, 2022
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD , May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
May 03, 2022
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors Targeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignancies Conference call scheduled for today at 4:30 p.m. ET.
Apr 25, 2022
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD , April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Mar 03, 2022
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
Feb 28, 2022
MacroGenics Announces Executive Promotion
ROCKVILLE, MD , Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief Operating Officer,
Feb 24, 2022
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeks Prioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and discontinuing development of flotetuzumab Presented encouraging preclinical combinatorial anti-tumor
Feb 14, 2022
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD , Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Feb 03, 2022
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in
Nov 03, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in
Nov 02, 2021
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
Investigational New Drug (IND) application submitted for MGD024, a next generation DART ® molecule targeting CD123 and CD3 for AML U.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP manufacturing facility to produce MARGENZA ® drug substance Discontinuing enrollment of Cohort A of
Oct 26, 2021
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD , Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Sep 16, 2021
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity; 4 of 16 (25%) achieved partial responses (two confirmed and two unconfirmed) Non-small cell